Astrazeneca Pharma India Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Through this approval, Acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL).

This regulatory clearance paves the way for the commercial launch and availability of Calquence in the Indian market.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company?s standalone net profit declined 42.3% to Rs 31.55 crore despite 38.9% increase in net sales to Rs 615.57 crore in Q3 FY26 over Q3 FY25.

The counter advanced 1.45% to end at Rs 8,291.50 on Friday, 10 April 2026.

Astrazeneca Pharma India announced that Jes?s Diaz-Ropero Esteso has resigned from the position of Non-Executive Director of AstraZeneca Pharma India and consequently from the Board Committee(s) on which he served, with immediate effect, due to a transition from current responsibilities.

Powered by Capital Market - Live News

The board of Astrazeneca Pharma India has appointed Sandhya Tejaswini Amanna as Director - Legal, with effect from 18 March 2026.

Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India rose 5.64% to Rs 32.59 crore in the quarter ended December 2025 as against Rs 30.85 crore during the previous quarter ended December 2024. Sales rose 38.90% to Rs 611.57 crore in the quarter ended December 2025 as against Rs 440.29 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News